Ignite Creation Date:
2024-05-06 @ 3:53 AM
Last Modification Date:
2024-10-26 @ 11:39 AM
Study NCT ID:
NCT02390648
Status:
COMPLETED
Last Update Posted:
2016-03-16
First Post:
2015-03-11
Brief Title:
Efficacy of Ginger as an Adjunctive Prophylaxis for Chemotherapy-induced Nausea and Vomiting
Sponsor:
Mahidol University
Organization:
Mahidol University
Study Overview
Official Title:
Efficacy of Ginger as an Adjunctive Prophylaxis for Chemotherapy-induced Nausea and Vomiting Randomised Double-blind Placebo-control Cross Over Study
Status:
COMPLETED
Status Verified Date:
2016-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Breast cancer patient receiving AC regimen chemotherapy Doxorubicin Cyclophosphamide who has nausea score from 40100 VAS or vomiting after the first or second cycle of chemotherapy is recruited The patient who meets the eligibility criteria and provides informed consent is randomised to receive either Ginger capsule 500 mg or placebo taking twice a day by mouth during the first 5 days of chemotherapy cycle The study drug will be switched on the subsequent cycle ie the patient who received Ginger capsule will receive placebo and vice versa The primary outcome is the nausea score and vomiting during the first 5 days of each chemotherapy cycle when receiving the study drug
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None